Of those patients who participated in PEGASUS-D FAS clinical trial, patient must sign the informed consent form in order to participate in this extension study. The medical records of the patients will be reviewed throughout the study.
Of those patients who participated in PEGASUS-D FAS clinical trial, patient must sign the informed consent form in order to participate in this extension study. * Collection of retrospective cohort data 1)The medical records from the subject's gastrectomy surgery date to Visit1 will be collected through a questionnaire and by reviewing the medical records of the patient. * Collection of prospective cohort data 1. Based on visit 1, if the subjects whose date of gastrectomy surgery date is more than 3 years(36 months) and less than 5 years(60 months), the subject should visit the institution at the time of 5 years(60 months, visit2) after gastrectomy surgery to evaluate data requested at visit2. 2. The medical records will be accessed and collected from the subject's gastrectomy surgery date up to 5 years(60 months)
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Enrollment
431
patients who continued UDCA 300mg prescription for the prevention of gallstone after PEGASUS-d trial
patients who discontinued UDCA 300mg prescription for the prevention of gallstone after PEGASUS-d trial
DoJoong Park
Seoul, South Korea
Proportion of subjects with gallstones formed
The proportion of subjects with gallstones formed after gastrectomy.
Time frame: at 3 years
Proportion of subjects with gallstones formed
The proportion of subjects with gallstones formed after gastrectomy.
Time frame: at 5 years
The incidence of symptomatic gallstones, acute cholecystitis, cholangitis, pancreatitis, liver abscess, and cholecystectomy.
The incidence of symptomatic gallstones, acute cholecystitis, cholangitis, pancreatitis, liver abscess, and cholecystectomy.
Time frame: at 3 years
The incidence of symptomatic gallstones, acute cholecystitis, cholangitis, pancreatitis, liver abscess, and cholecystectomy.
The incidence of symptomatic gallstones, acute cholecystitis, cholangitis, pancreatitis, liver abscess, and cholecystectomy.
Time frame: at 5 years
The duration of UDCA
The duration of UDCA
Time frame: up to 5 years
The dose of UDCA
The dose of UDCA
Time frame: up to 5 years
The recurrence rate of gastric cancer
The recurrence rate of gastric cancer
Time frame: up to 5 years
The survival rate of gastric cancer
The survival rate of gastric cancer
Time frame: up to 5 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.